Overview

Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of niraparib combined with oral etoposide in platinum resistant or platinum refractory recurrent ovarian cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborator:
Zai Lab (Shanghai) Co., Ltd.
Treatments:
Etoposide
Etoposide phosphate
Niraparib